Dyadic International, Inc. (NASDAQ:DYAI) Short Interest Down 22.7% in January

Dyadic International, Inc. (NASDAQ:DYAI) saw a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 121,300 shares, a drop of 22.7% from the December 31st total of 157,000 shares. Based on an average trading volume of 91,200 shares, the days-to-cover ratio is presently 1.3 days. Currently, 0.6% of the company’s shares are short sold.

Institutional Trading of Dyadic International

Several institutional investors have recently made changes to their positions in the company. Inlet Private Wealth LLC purchased a new stake in Dyadic International in the fourth quarter valued at approximately $52,000. Truist Financial Corp purchased a new stake in Dyadic International in the fourth quarter valued at approximately $428,000. Finally, Chapin Davis Inc. raised its position in Dyadic International by 2.5% in the third quarter. Chapin Davis Inc. now owns 868,301 shares of the biotechnology company’s stock valued at $903,000 after purchasing an additional 21,000 shares during the period. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Dyadic International Price Performance

Shares of DYAI opened at $1.49 on Friday. The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.15. The business has a 50-day moving average of $1.67 and a 200-day moving average of $1.39. Dyadic International has a 1 year low of $0.93 and a 1 year high of $2.67. The company has a market capitalization of $44.09 million, a price-to-earnings ratio of -6.48 and a beta of 0.89.

Dyadic International (NASDAQ:DYAI) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.06. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. The business had revenue of $1.96 million for the quarter, compared to analyst estimates of $1.05 million. During the same period last year, the company posted ($0.06) EPS. As a group, equities research analysts anticipate that Dyadic International will post -0.18 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Dyadic International in a research report on Thursday, November 14th.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.